Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Preradiotherapy hemoglobi… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Preradiotherapy hemoglobin level but not microvessel density predicts locoregional control and survival in laryngeal cancer treated with primary radical radiotherapy.

Artikel i vetenskaplig tidskrift
Författare Hedda Haugen
Bengt Magnusson
Claes Mercke
Marie Svensson
Publicerad i Clinical cancer research : an official journal of the American Association for Cancer Research
Volym 10
Nummer/häfte 23
Sidor 7941-9
ISSN 1078-0432
Publiceringsår 2004
Publicerad vid Odontologiska institutionen
Institutionen för särskilda specialiteter, Avdelningen för onkologi
Sidor 7941-9
Språk en
Länkar dx.doi.org/10.1158/1078-0432.CCR-04...
Ämnesord Adult, Aged, Aged, 80 and over, Biological Markers, analysis, Carcinoma, Squamous Cell, blood, pathology, radiotherapy, Cell Differentiation, Follow-Up Studies, Hemoglobin A, analysis, Humans, Immunoenzyme Techniques, Laryngeal Neoplasms, blood, pathology, radiotherapy, Microcirculation, Middle Aged, Neoplasm Recurrence, Local, Preoperative Care, Prognosis, Radiotherapy Dosage, Survival Rate
Ämneskategorier Patologi, Oral patologi och rättsodontologi

Sammanfattning

PURPOSE: To evaluate the roles of preradiotherapy hemoglobin level and microvessel density (MVD) as predictive factors for tumor control and survival in patients with laryngeal cancer treated with primary radiotherapy. EXPERIMENTAL DESIGN: Two hundred and fourteen patients with stage I-IV laryngeal cancer were included in the analysis. Patients were treated with once daily fractionated radiotherapy over 6.5 weeks or twice daily fractionated radiotherapy over 4.5 weeks up to total doses of 62 to 68 Gy. Preradiotherapy hemoglobin levels were obtained from patient journals, and pretreatment tumor biopsies were stained with CD34 antibody for the counting of microvessels. The prognostic implication of preradiotherapy hemoglobin level and MVD on tumor control and survival was tested. RESULTS: Five-year locoregional control probability was 88.9% for patients with preradiotherapy hemoglobin levels >137.5 g/L (median) and 64.4% for patients with preradiotherapy hemoglobin levels <137.5 g/L (P = 0.01). The corresponding figures for disease-free survival were 87.8 and 62.8% (P = 0.007), respectively, and for overall survival 58.1 and 40.3% (P < 0.001), respectively. In multivariate analysis, tumor stage and preradiotherapy hemoglobin level were significant prognostic factors for locoregional control and disease-free survival, whereas tumor stage, preradiotherapy hemoglobin-level, gender, and age were significant prognostic factors for overall survival. No correlation was found between MVD and tumor control and survival. CONCLUSION: Preradiotherapy hemoglobin level, but not MVD, predicts locoregional control and survival in patients with laryngeal cancer treated with radiotherapy.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?